Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0819 IPOs Harmony Inhibrx
BioCentury & Getty Images

Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

Aug 20, 2020 | 1:34 AM GMT

Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx and

Read the full 430 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE